Please login to the form below
Primaxin
This page shows the latest Primaxin news and features for those working in and with pharma, biotech and healthcare.
FDA accepts priority review for Merck’s antibiotic combo Recarbrio
The regimen combines Merck’s imipenem/cilastatin duo – sold as Primaxin as a broad-spectrum antibiotic – with a new beta lactamase inhibitor called relebactam that is designed to restore the susceptibility
Latest news
-
Merck preps regulatory filings for much-needed antibiotic combo
The regimen combines Merck’s own Primaxin with new beta lactamase inhibitor relebactam. ... The regimen combines Merck’s imipenem/cilastatin duo - sold as Primaxin as a broad-spectrum antibiotic for decades - with a new beta lactamase inhibitor
-
Merck starts pivotal trials of new antibiotic combination
The drug is designed to inhibit a key resistance mechanism that inhibits the effectiveness of beta lactam antibiotics, and will be studied in phase III in combination with Merck's Primaxin
-
News in brief, January 16, 2007
A Pharmacor report, Emerging Antibacterial Agents, found that J&Jís Levaquin, SAís Tavanic, DSís Cravit, Merckís Primaxin, Abbottís.
More from news
Approximately 1 fully matching, plus 3 partially matching documents found.
Subscribe to our email news alerts
- Market Access Director, six figure base salary and £5K joining b...
- Highly competitive salary
- Senior Medical Copywriter - Highly Awarded Advertising Agency
- £50,000 - £60,000 yearly
- Account Director, Healthcare Marketing Creative Agency, Fixed te...
- Highly competitive salary
- Account Manager, 6 month contract, Healthcare Brand communicatio...
- Highly competitive salary
- Home Based Account Manager, Medical Communications, UK, Pharma/M...
- Highly competitive salary
- Account Manager, Healthcare Marketing Creative Agency, Fixed ter...
- Highly competitive salary
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
- BMS and Janssen’s antithrombotic granted FDA fast track designation
- Pfizer’s antibiotic combination shows promise in treating multi-drug resistant infections
- Sanofi's frexalimab shows promise in relapsing forms of MS
- EMA recommends revoking marketing authorisation for Novartis’ sickle cell disease drug
- Pfizer’s RSV vaccine approved by FDA for older adults
- Navigating patients step by step on their clinical trial journey
- Innovative Trials responds to national recommendations to tackle UK clinical trial decline
- AstraZeneca shares positive phase 3 results for Tagrisso in lung cancer
- BMS presents positive four-year results for Opdivo combination in lung cancer
- Tuberculosis – why it remains a major global public health challenge
- Whitepaper: Closing the gap with compelling healthcare communications
No results were found
PMHub
Havas Life Medicom
We are a fully integrated agency that is 100% dedicated to creating standout communications in healthcare. Our success starts by...
Latest intelligence
- Tuberculosis – why it remains a major global public health challenge
- Innovative collaboration is required to address the major public health challenges around TB and expedite drug development...
- Whitepaper: Closing the gap with compelling healthcare communications
- Want to learn how to close the distance between a person’s current health and their healthiest possible self?...
- Healing the Healers
- Because if we do not heal the healers, who is going to heal us?...
